Paliperidonă Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidonă Teva, is a atypical antipsychotic presented as an intramuscular injection for long‑acting schizophrenia maintenance therapy in adults. It is administered by a healthcare professional to help control psychotic symptoms over weeks to months.

GNH USA supplies Paliperidonă Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone palmitate is an atypical antipsychotic indicated for the treatment of schizophrenia and related psychotic disorders. - Schizophrenia: reduces relapse risk and stabilises symptoms during maintenance therapy. - Schizoaffective disorder: helps control mood‑related psychotic episodes. - Bipolar I disorder (maintenance): provides long‑acting control of manic or mixed episodes when oral therapy is unsuitable.

Adverse reactions may range from mild to severe and should be monitored throughout treatment.

Common Side Effects: - Injection site pain or erythema. - Weight gain. - Akathisia or restlessness. - Somnolence or fatigue. - Constipation. - Increased prolactin levels.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome. - Tardive dyskinesia. - Severe orthostatic hypotension. - Seizures. - Hyperglycaemia or new‑onset diabetes. - Agranulocytosis (very rare).

Before initiating therapy, clinicians should evaluate patient history and monitor ongoing safety parameters. - Cardiovascular assessment: obtain baseline ECG and monitor for QT prolongation. - Metabolic monitoring: track weight, glucose and lipid profiles regularly. - Prolactin surveillance: assess for galactorrhoea, menstrual changes or sexual dysfunction. - Pregnancy and lactation: weigh benefits against potential fetal or infant risks. - Drug‑specific contraindications: avoid in patients with known hypersensitivity to paliperidone or the formulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidone palmitate may interact with other medicines that affect its metabolism or cardiac conduction.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase paliperidone exposure. - QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce efficacy. - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation. - Antihypertensives: may potentiate orthostatic hypotension. - Antidiabetic drugs: monitor glucose as paliperidone can affect glycaemic control.